



## PRESS RELEASE

**Axxam and Collectis bioresearch announce their collaboration to offer a new generation of cell based assays**

**January 17, 2014** – Axxam (Milan), a leading provider of discovery services including assay development for high-throughput screening, and Collectis bioresearch (Paris), the cell engineering expert, have started a collaboration to offer to the Life Science industry an extensive range of integrated discovery services based on genomic engineering technologies.

Under the joint offering, clients will be provided with a one-stop-shop approach for the generation of cell-based assays through genomic engineering. Genes of interest will be modified using Collectis bioresearch's proprietary genome engineering technologies, after which functional cellular assays will be developed using Axxam's expertise and technologies for cell line generation. Both the required gene modification and the resulting functionality change will be experimentally demonstrated. Finally, validated assays for screening and profiling experiments will be provided to the client. With the currently available genome engineering technologies virtually any gene, at any position, in any cell type can be addressed for a wide range of applications such as knock-in insertions, knock-out deletions, reporter cell line generations and others.

Stefan Lohmer, Chief Executive Officer at Axxam, commented: *"Genomic engineering technologies will open a new chapter for the generation of cell-based assays. For the first time, any modification at the genomic level can be introduced into a cellular assay, thereby increasing significantly the repertoire for generating the most relevant assay format for a given target. We have been very impressed by Collectis' success-proven expertise in the genomic engineering field and are extremely pleased to join our complementary forces to present to clients this unique combination resulting in a new generation of cellular assays."*

Jean-Charles Epinat, Chief Executive Officer at Collectis bioresearch, stated: *"We are pleased to combine our expertise with Axxam's to offer our pharma and biotech partners a complete solution for drug discovery. We have found in Axxam a first-class partner for cellular assay development and there is a perfect match between our two companies' technologies and objectives, allowing us to further extend our market reach. This partnership positions us as a major player in cell line engineering for Life Science discovery."*

**About Axxam ([www.axxam.com](http://www.axxam.com))**

Axxam is a privately owned contract research and discovery company. The company has developed a proven track record as a third party research and discovery services provider for the Life Science industry. In addition, Axxam conducts several discovery programs for selected targets which are carried out in partnership with other companies or non-profit organizations.

**About Collectis bioresearch**

Established in 2008 as a subsidiary of Collectis (Alternext: ALCLS), Collectis bioresearch provides Life Science researchers with genome customization tools and services, such as the award-winning Custom TALEN™ Services. Based on these in-field expertise and proprietary technologies, Collectis bioresearch enables precise modifications of DNA sequences in a target genome, whether it is a cell line, a primary cell or a stem cell. Collectis bioresearch brings to the bench engineered cell lines and cellular models with the

desired characteristics for optimal relevance and performance. For further information please visit our website [www.collectis-bioresearch.com](http://www.collectis-bioresearch.com) or [techno@collectis-bioresearch.com](mailto:techno@collectis-bioresearch.com)

### **Disclaimer**

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe for shares in Collectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements.

### **For more information, please contact:**

#### **Axxam SpA**

Dr. Doris Hafenbradl

Phone: +39 02 2105680

Email: [doris.hafenbradl.dh@axxam.com](mailto:doris.hafenbradl.dh@axxam.com)

#### **Collectis bioresearch**

Jennifer Moore

Phone: +33 (0)1 81 69 16 00

Email: [media@collectis.com](mailto:media@collectis.com)